Antiangiogenic therapy for high-grade gliomas

Area of Science:

• Oncology
• Vascular Biology
• Pharmacology

Background:

• High-grade gliomas (HGG) exhibit significant tumor angiogenesis, the formation of new blood vessels.
• Tumor angiogenesis is crucial for supporting uncontrolled cancer cell growth.
• Antiangiogenic therapies were developed to target this process, with strategies focusing on vascular endothelial growth factor (VEGF) or its receptor (VEGFR).

Purpose of the Study:

• To evaluate the role and efficacy of antiangiogenic therapies in the treatment of recurrent high-grade gliomas.
• To review the current literature on antiangiogenic therapy for HGG, including its benefits and challenges.

Main Methods:

• Review of emerging literature on antiangiogenic therapy for recurrent HGG.
• Analysis of treatment strategies, including ligand-based (e.g., targeting VEGF) and receptor-based (e.g., targeting VEGFR) approaches.
• Consideration of combination therapy with cytotoxic chemotherapy.

Main Results:

• Antiangiogenic therapy, particularly ligand-based, is increasingly used for recurrent HGG.
• Reported response rates range from 30-60%, with 6-month progression-free survival between 25-50%.
• Challenges include managing side effects, optimizing timing with surgery, and establishing clear response measures and dose-response relationships.

Conclusions:

• Ligand-based antiangiogenic therapy, exemplified by bevacizumab, shows promise as a targeted treatment for HGG.
• Further research is essential to identify optimal patient populations, dosing, scheduling, and combination strategies.
• Validated response measures are needed to better assess treatment effectiveness.